Medicare Rx Compromise Talks Will Focus On Comprehensive Bills – AARP
Executive Summary
AARP believes that a compromise on a comprehensive Medicare drug benefit could be negotiated in the Senate over the August recess
You may also be interested in...
Medicare Rx Moves To Campaign Trail; AARP Endorses Stripped Down Bill
The Medicare prescription drug benefit debate is moving from Capitol Hill to the campaign trail after the Senate failed to reach agreement on a bill before the August recess
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials